



## Philippa Lewis discusses distribution and integration agreements

For Immediate Release

July 6, 2015

**Sydney, Australia** – Simavita Limited (ASX: SVA; TSX-V: SV) (“Simavita” or the “Company”) is pleased to invite investors to listen to an audio recording of CEO, Philippa Lewis, providing further insight into the Hartmann and Bunzl distribution agreements and the work being undertaken to integrate the Company’s SIM solution with Electronic Health Record solutions provided by US-based MatrixCare.

In this audiocast, Mrs. Lewis discusses the following:

- An overview of the Hartmann and Bunzl sales and marketing agreements, how they will impact both Simavita and partner customers, and why each relationship is valuable; and
- More detail in respect of the recent MatrixCare interoperability announcement – what it means, why it has the ability to make a significant impact on Simavita’s penetration of the US market and how Electronic Health Records are applied in the US.

To listen to the audiocast, please copy the following link into your browser:

<http://brrmedia.com/event/139237>

For further information, see our website ([www.simavita.com](http://www.simavita.com)) or contact the persons outlined below.

Company	Media and Investor Relations
Philippa Lewis, Chief Executive Officer T: +61 2 8405 6381	<i>In Australia:</i> Jane Lowe, IR Department E: <a href="mailto:jane.lowe@irdepartment.com.au">jane.lowe@irdepartment.com.au</a> T: +61 411 117 774
Thomas Howitt, Chief Financial Officer T: +61 418 351 127	

### About Simavita

Simavita is a medical device company operating in the digital healthcare sector that has developed an innovative, world first solution for the management of urinary incontinence, with a focus on the elderly. The first product is the SIM™ platform technology which is an instrumented incontinence assessment application that provides evidence based incontinence management care plans to the residential aged care market.

### About SIM™

SIM™ is a wireless sensor technology that delivers evidence-based instrument incontinence data on individuals. SIM™ provides user friendly tools and software to assess the incontinence condition and to help plan better outcomes. SIM™ is used to detect, record and report incontinence events during a compulsory or recommended assessment period in residential aged care facilities to develop an evidence-based incontinence care plan.

Conducting assessments is mandatory in many countries and the incontinence assessment creates an influential element of care of each individual. For more information on Simavita or SIM™, please visit [www.simavita.com](http://www.simavita.com).

*The TSX Venture Exchange has in no way passed upon the merits of the transactions set out herein and has neither approved nor disapproved the contents of this press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this Release.*

*Except for historical information, this announcement may contain forward-looking statements that reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause, but are not limited to, the anticipated date of on the ASX, changing market conditions, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.*